EP3402514A4 - Methods and compositions for influenza vaccination - Google Patents

Methods and compositions for influenza vaccination Download PDF

Info

Publication number
EP3402514A4
EP3402514A4 EP17739063.0A EP17739063A EP3402514A4 EP 3402514 A4 EP3402514 A4 EP 3402514A4 EP 17739063 A EP17739063 A EP 17739063A EP 3402514 A4 EP3402514 A4 EP 3402514A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
influenza vaccination
vaccination
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17739063.0A
Other languages
German (de)
French (fr)
Other versions
EP3402514A1 (en
Inventor
Frank R. Jones
Joseph Balint
Elizabeth GABITZSCH
Yvette Latchman
Adrian RICE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Etubics Corp
Original Assignee
Etubics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Etubics Corp filed Critical Etubics Corp
Publication of EP3402514A1 publication Critical patent/EP3402514A1/en
Publication of EP3402514A4 publication Critical patent/EP3402514A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP17739063.0A 2016-01-15 2017-01-13 Methods and compositions for influenza vaccination Withdrawn EP3402514A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662279267P 2016-01-15 2016-01-15
US201662294840P 2016-02-12 2016-02-12
PCT/US2017/013480 WO2017123976A1 (en) 2016-01-15 2017-01-13 Methods and compositions for influenza vaccination

Publications (2)

Publication Number Publication Date
EP3402514A1 EP3402514A1 (en) 2018-11-21
EP3402514A4 true EP3402514A4 (en) 2019-06-26

Family

ID=59311638

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17739063.0A Withdrawn EP3402514A4 (en) 2016-01-15 2017-01-13 Methods and compositions for influenza vaccination

Country Status (10)

Country Link
US (1) US20190022209A1 (en)
EP (1) EP3402514A4 (en)
JP (1) JP2019501945A (en)
KR (1) KR20180101529A (en)
CN (1) CN108778326A (en)
AU (1) AU2017207448A1 (en)
CA (1) CA3010874A1 (en)
HK (1) HK1259146A1 (en)
TW (1) TW201726165A (en)
WO (1) WO2017123976A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250046341A (en) 2017-02-27 2025-04-02 플루젠, 인코퍼레이티드 Immunogenic compositions against influenza
EP3727444A1 (en) 2017-12-18 2020-10-28 Intervet International B.V. Swine influenza a virus vaccine
KR102371663B1 (en) * 2020-01-21 2022-03-04 코오롱생명과학 주식회사 Adenovirus vector
CN116963768A (en) * 2020-11-18 2023-10-27 格雷菲克斯公司 Design of an optimized universal influenza vaccine, its design and use
KR20240051039A (en) 2022-10-11 2024-04-19 경희대학교 산학협력단 Virus-like particles combination vaccines comprising influenza A virus antigen protein HA, NA or M2e5x
EP4704889A1 (en) 2023-05-04 2026-03-11 ImmunityBio, Inc. Adenoviral vector transduced apheresis product

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009006479A2 (en) * 2007-07-02 2009-01-08 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
US20110182938A1 (en) * 2010-01-26 2011-07-28 Weiner David B Influenza nucleic acid molecules and vaccines made therefrom

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102549152B (en) * 2009-07-31 2015-11-25 帕克斯瓦克斯股份有限公司 Based on the carrier of adenovirus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009006479A2 (en) * 2007-07-02 2009-01-08 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
US20110182938A1 (en) * 2010-01-26 2011-07-28 Weiner David B Influenza nucleic acid molecules and vaccines made therefrom

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ASEEM PANDEY ET AL: "Impact of Preexisting Adenovirus Vector Immunity on Immunogenicity and Protection Conferred with an Adenovirus-Based H5N1 Influenza Vaccine", PLOS ONE, vol. 7, no. 3, 4 March 2012 (2012-03-04), pages e33428, XP055265181, DOI: 10.1371/journal.pone.0033428 *
BELSHE ET AL: "The need for quadrivalent vaccine against seasonal influenza", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 28, 7 September 2010 (2010-09-07), pages D45 - D53, XP027215024, ISSN: 0264-410X, [retrieved on 20100813] *
DONGXIAO DONG ET AL: "Adenovirus-mediated co-expression of the TRAIL and HN genes inhibits growth and induces apoptosis in Marek?s disease tumor cell line MSB-1", CANCER CELL INTERNATIONAL, BIOMED CENTRAL, LONDON, GB, vol. 15, no. 1, 18 February 2015 (2015-02-18), pages 20, XP021214136, ISSN: 1475-2867, DOI: 10.1186/S12935-015-0172-6 *
FRANK R JONES ET AL: "Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 29, no. 40, 10 July 2011 (2011-07-10), pages 7020 - 7026, XP028283453, ISSN: 0264-410X, [retrieved on 20110727], DOI: 10.1016/J.VACCINE.2011.07.073 *
See also references of WO2017123976A1 *

Also Published As

Publication number Publication date
WO2017123976A1 (en) 2017-07-20
JP2019501945A (en) 2019-01-24
CA3010874A1 (en) 2017-07-20
WO2017123976A8 (en) 2017-08-17
US20190022209A1 (en) 2019-01-24
EP3402514A1 (en) 2018-11-21
AU2017207448A1 (en) 2018-07-26
HK1259146A1 (en) 2019-11-29
TW201726165A (en) 2017-08-01
KR20180101529A (en) 2018-09-12
CN108778326A (en) 2018-11-09

Similar Documents

Publication Publication Date Title
EP3322441A4 (en) Vaccine compositions
EP3452596A4 (en) Oligonucleotide compositions and methods thereof
EP3442543A4 (en) Compositions and methods for neuralgenesis
EP3188749A4 (en) Tolerogenic compositions and methods
EP3242940A4 (en) Methods and compositions for combination immunotherapy
EP3286213A4 (en) Methods and compositions for combination immunotherapy
EP3256140A4 (en) Methods and compositions for ebola virus vaccination
EP3096757A4 (en) Apilimod compositions and methods for using same
EP3131579A4 (en) Vaccine adjuvant compositions
EP3198275A4 (en) Sterilization compositions and methods
EP3253389A4 (en) Apilimod compositions and methods for using same
EP3191114A4 (en) Occidiofungin formulations and uses thereof
EP3139901A4 (en) Non-petrochemically derived cationic emulsifiers and related compositions and methods
EP3190886A4 (en) Compositions and methods of use thereof
EP3402514A4 (en) Methods and compositions for influenza vaccination
EP3139741A4 (en) Methods and compositions comprising 10-hydroxy-2-decenoic acid
EP3185873A4 (en) Pharmaceutical composition and methods
EP3130340A4 (en) Isoacteoside derivative and preparation method and use thereof
GB201801566D0 (en) Methods and compositions for nanormulsion vaccine formulations
EP3169699A4 (en) Cancer vaccine compositions and methods of use thereof
EP3137111A4 (en) Compositions and methods for intradermal vaccine delivery
EP3305328A4 (en) Non-gelatin vaccine protectant composition and live attenuated influenza vaccine
EP3113774A4 (en) Compositions of grapiprant and methods for using the same
EP3097420A4 (en) Methods and compositions for immune dis-inhibition
EP3290049A4 (en) Allergy vaccine composition

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180717

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190528

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/23 20060101AFI20190522BHEP

Ipc: A61K 39/00 20060101ALI20190522BHEP

Ipc: A61K 39/145 20060101ALI20190522BHEP

Ipc: C12N 15/00 20060101ALI20190522BHEP

Ipc: A61K 39/12 20060101ALI20190522BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200629

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20200811